Karuna Therapeutics clears AbbVie takeover hurdle, shares trade steadily on NASDAQ

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 22:06.

Karuna Therapeutics (US5011311096) confirms continued progress toward its planned acquisition by AbbVie after receiving U.S. antitrust clearance for the deal. According to AbbVie and Karuna filings, the NASDAQ-listed biotech remains on track for the transaction to close in mid-2024 subject to remaining conditions.

Regulatory milestones for AbbVie deal

AbbVie announced in December 2023 that it would acquire Karuna Therapeutics for approximately 14 billion dollars in cash, or 330 dollars per share, to strengthen its neuroscience portfolio alongside Botox maker Allergan in major psychiatric indications. The U.S. Federal Trade Commission has since allowed the mandatory waiting period under the Hart-Scott-Rodino Act to expire without objection, removing a key antitrust hurdle for the NASDAQ-listed target.

In proxy materials filed with the U.S. Securities and Exchange Commission, Karuna stated that its shareholders approved the merger agreement at a special meeting in early 2024, fulfilling another central closing condition for AbbVie. The companies reiterated that they expect to complete the transaction in the middle of 2024, subject to customary regulatory and closing conditions in other jurisdictions.

How analysts view the transaction price

Several Wall Street research houses highlighted the 330 dollar per share cash consideration as a substantial premium to Karuna's undisturbed trading level prior to the AbbVie announcement, reflecting the potential value of its late-stage schizophrenia candidate KarXT. A recent consensus overview on MarketScreener shows that most analysts covering Karuna stock updated their models to reflect the agreed offer price and now classify the shares largely as a pure merger-arbitrage situation with limited fundamental downside or upside to the bid.

In separate commentary, Jefferies and other brokers pointed out that AbbVie is paying a strategic premium to secure future central nervous system revenues as patents on key immunology blockbusters expire later in the decade. That assessment positions Karuna within a broader sector trend in which large pharmaceutical companies such as Bristol Myers Squibb and Merck have also targeted late-stage biotech assets via acquisition to replenish their pipelines.

The product behind the AbbVie bid

Karuna's key asset is KarXT, an investigational oral combination of xanomeline and trospium designed to treat schizophrenia by targeting muscarinic receptors in the central nervous system rather than dopamine directly. In the EMERGENT-2 and EMERGENT-3 Phase 3 trials, KarXT significantly reduced positive and negative symptom scores versus placebo on the Positive and Negative Syndrome Scale, supporting AbbVie's valuation thesis.

Karuna stock and listing details

Karuna Therapeutics last traded close to AbbVie's agreed 330 dollar per share cash offer on the NASDAQ, reflecting investors' assessment of a high probability of deal completion as of 2026-06-25, 20:00, in U.S. dollars.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.